Anti-inflammatory and anti-atherogenic role of BMP receptor II in atherosclerosis

Future Cardiology

Volumn 9, Issue 5, 2013, Pages 619-622

  Simic, Tatjana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Atherosclerosis; BMPRII; Endothelial cell; Inflammation

Indexed keywords

APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; COMPACTIN; INTERCELLULAR ADHESION MOLECULE 1; ROSUVASTATIN; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIATHEROGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEIN RECEPTORS; HUMANS; NF-KAPPA B;

EID: 84884140947     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.61     Document Type: Article

References (14)

1. Kim CW, Song H, Kumar S et al. Anti-inflammatory and anti-atherogenic role of BMP receptor II in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33, 1350-1359 (2013).
2. Derynck R, Miyazono K. TGF-b and the TGF-b family. In: The TGF-b Family. Derynck R, Miyazono K (Eds). Cold Spring Harbor Press, NY, USA, 29-44 (2008).
3. Chang K, Weiss D, Suo J et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 116, 1258-1266 (2007).
4. Miriyala S, Gongora Nieto MC, Mingone C et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113, 2818-2825 (2006).
5. Yao Y, Bennett BJ, Wang X et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ. Res. 107, 485-494 (2010).
6. Derwall M, Malhotra R, Lai CS et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler. Thromb Vasc. Biol. 32, 613-622 (2012).
7. Hogan BL. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 6, 432-438 (1996).
8. Massagué J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 1, 169-178 (2000).
9. Nam D, Ni CW, Rezvan A et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 297, H1535-H1543 (2009).
10. Sorescu GP, Song H, Tressel SL et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a Nox1-based NADPH oxidase. Circ. Res. 95, 773-779 (2004).
11. Ni CW, Qiu H, Rezvan A et al. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood 116, e66-e73 (2010).
12. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The international PPH Consortium. Nat. Genet. 26, 81-84 (2000).
13. Yu PB, Beppu H, Kawai N et al. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 280, 24443-24450 (2005).
14. Wong WK, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 33, 438-446 (2005).